
    
      This protocol is intended to provide access to bemarituzumab (FPA144 an investigational
      agent) to a single patient with recurrent bladder cancer who had a response to study drug on
      FPA144-001. That study is closing and this expanded access protocol allows this single
      patient to continue receiving this agent.
    
  